Skip to main content

Table 4 Significantly modified proteins in post treated placebo versus pre treated placebo asthmatic patients

From: Network analysis of quantitative proteomics on asthmatic bronchi: effects of inhaled glucocorticoid treatment

Swiss Prot Acc. No. Symbol Entrez Gene Name Fold Change Location Protein Class
P60709 ACTB actin, beta -1.66 Cytoplasm actin and actin related protein
P05783 KRT18 keratin 18 1.31 Cytoplasm structural protein
P01009 SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 2.34 Extracellular space serine protease inhibitor
  1. © 2000-2011 Ingenuity Systems, Inc. All rights reserved.
  2. All listed proteins showed a statistically significant difference (p value < 0.05) between the groups using a Student's t-test. The fold change for each protein is calculated by dividing the average ratio of the placebo post treated biopsy with the average ratio of the paired pre placebo biopsy. The negative fold change indicates down regulation of protein expression by placebo, while the positive fold change indicates up regulation by placebo. The cell location of the protein is annotated by IPA. The protein class is determined using the PANTHER Classification System.